Joint Operational Medicine Information Systems (JOMIS)



In FY23, the Joint Operational Medicine Information Systems (JOMIS) Program Management Office (PMO) successfully implemented all DOT&E recommendations from the September 2022 early fielding report on the Medical Common Operating Picture (MedCOP) application, and further applied lessons learned to all other JOMIS applications. In addition to these changes, the PMO engaged with DOT&E to implement persistent cyber operations (PCO) on multiple JOMIS products; PCO will begin after the successful execution of planned cyber survivability operational test events.

SYSTEM DESCRIPTION

The JOMIS PMO provides several capabilities, referred to as managed applications, to the warfighter. The managed applications are as follows.

- **MedCOP:** Provides a web-based interactive decision-support platform arming command surgeons and medical commanders with the ability to view, analyze, report, and share Health Service Support/Force Health Protection status near real-time to inform current decision making and future planning.
- **Operational Medicine Care Delivery Platform (OpMed CDP):** Enables health care delivery at the point of injury, during transport, and during care at lower-level medical facilities such as field hospitals, through a combination of commercial off-the-shelf and government off-the-shelf capabilities.
- **MHS GENESIS Theater (MHSG-T):** Enables health care delivery and documentation of patient care to all categories of patients at forward-deployed medical facilities in a disconnected environment.
- **Operational Medicine Data Service (OMDS):** Serves as the data-centric infrastructure providing critical data transport and management capabilities that are key to all JOMIS operational medicine modernization activities.
- **Theater Blood Mobile (TBLD-M):** Provides the Services and blood operations community with the capability to manage and electronically document blood product donations; blood asset inventory and transfusions; and transmittable disease testing and tracking in both connected and disconnected, intermittent, and low-bandwidth operational environments. TBLD-M also provides real-time blood tracking of Walking Blood Bank candidates at both the local and aggregated level.

MISSION

Warfighters will use the managed applications acquired through the JOMIS PMO to support the five operational medicine healthcare functions: Medical Command and Control (MedC2), Medical Situational Awareness (MedSA), Medical Logistics (MedLOG), Healthcare Delivery (HCD), and Patient Movement (PM). See Table 1 below.

PROGRAM

All of the JOMIS managed applications except MHSG-T are using the software acquisition pathway. MHSG-T is jointly

Table 1. JOMIS Managed Applications

	MedC2	MedSA	MedLOG	HCD	PM
MedCOP	X	X	X	X	X
OpMed CDP				X	
MHSG-T			X	X	
OMDS	X	X	X	X	X
TBLD-M			X	X	

developed with the Defense Healthcare Management System Modernization (DHMSM) PMO and is an Acquisition Category ID program. DOT&E approved the Overarching JOMIS Test and Evaluation Strategy in September 2022, and issued an early fielding report on MedCOP in September 2022. The other four managed applications have not yet been operationally tested or fielded.

In implementing PCO, the JOMIS PMO joins the DHMSM PMO in piloting a program level integration of PCO, successfully used at combatant commands, to help ensure the cyber survivability posture of developed capabilities are rigorously assessed throughout the life cycle of the program, rather than limited to the acquisition and development phases.

» MAJOR CONTRACTORS

- Accenture Federal Services – Arlington, Virginia (MedCOP)
- ViiMed – Washington, DC (OpMed CDP)
- T6 Health Systems – Chesnut Hill, Massachusetts (OpMed CDP)
- Air Force Research Laboratory (OpMed CDP)
- Leidos – Reston, Virginia (MHSG-T)
- Oracle Health – Austin, Texas (MHSG-T)
- Dark Wolf Solutions – Herndon, Virginia (OMDS, TBLD-M)
- Omni Federal – Gainesville, Virginia (OMDS)

TEST ADEQUACY

The Joint Interoperability Test Command (JITC) conducted an operational assessment in accordance with a DOT&E-approved test plan of MedCOP at U.S. Central Command (USCENTCOM) in January 2023, which was observed by DOT&E. However, limitations on the number of users prevented JITC from assessing progress towards effectiveness and suitability. As a result, DOT&E did not write an independent assessment report.

JITC conducted the first phase of required cyber survivability operational test events in August 2023, in order to assess survivability of MedCOP.

JITC will conduct additional operational testing events, to include cyber survivability test events, during FY24, on all JOMIS applications, after which DOT&E will submit reports.

PERFORMANCE

» EFFECTIVENESS, SUITABILITY, AND SURVIVABILITY

JITC will conduct operational testing in FY24 on all the JOMIS managed applications, from which DOT&E will determine operational effectiveness, suitability, and survivability.

RECOMMENDATIONS

The JOMIS PMO and Program Executive Office Defense Healthcare Management Systems should:

1. Continue close collaboration with JITC and DOT&E throughout the development and testing of all JOMIS capabilities to conduct operational testing that evaluates whether each managed application is operationally effective, suitable, and survivable.
2. Engage with the DHMSM PMO to explore the feasibility of using MHSG-T as a backup capability for MHS GENESIS at all MHS GENESIS facilities, to ensure continuity of care in a denied, degraded, intermittent, or limited communications environment.
3. Ensure that the upcoming operational tests have sufficient users to support assessments of effectiveness and suitability.